Moderna's full pipeline may fuel long-term growth.
Moderna is working to build a seasonal vaccines portfolio to spur growth. The FDA this week said it won’t review the biotech’s flu vaccine candidate. But, as demand for coronavirus vaccines waned ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results